Maturitas
Volume 57, Issue 4 , Pages 361-369 , 20 August 2007

Efficacy and tolerability of estradiol 1mg and drospirenone 2mg in postmenopausal korean women: A double-blind, randomized, placebo-controlled, multicenter study

  • B.S. Lee

      Affiliations

    • Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Seoul, Republic of Korea
    • ,
  • B.M. Kang

      Affiliations

    • Department of Obstetrics and Gynecology, College of Medicine, Ulsan University, Seoul, Republic of Korea
    • ,
  • B.K. Yoon

      Affiliations

    • Department of Obstetrics and Gynecology, College of Medicine, Sungkyunkwan University, Seoul, Republic of Korea
    • ,
  • H. Choi

      Affiliations

    • Department of Obstetrics and Gynecology, College of Medicine, Inje University, Seoul, Republic of Korea
    • ,
  • H.M. Park

      Affiliations

    • Department of Obstetrics and Gynecology, College of Medicine, Chungang University, Seoul, Republic of Korea
    • ,
  • J.G. Kim

      Affiliations

    • Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, 28 Yeongun-dong, Jongro-ku, Seoul 110-744, Republic of Korea
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, College of Medicine, Seoul National University 28 Yeongun-dong, Jongro-ku, Seoul 110-744, Republic of Korea. Tel.: +82 2 2072 3256; fax: +82 2 742 2028.

Received 15 December 2006 ,Revised 7 March 2007 ,Accepted 14 March 2007.

References 

  1. Witt DM, Lousberg TR. Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother. 1997;31:745–755
  2. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systemic review. Climacteric. 2001;4:58–74
  3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  4. Writing group for the Women's Health Initiative investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  5. The Women's Health Initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  6. Oelkers W. Drospirenone—a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care. 2000;5(Suppl. 3):17–24
  7. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54:243–251
  8. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci. 1995;761:311–335
  9. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002;3:211–224
  10. Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric. 2003;6(Suppl. 2):17–23
  11. Elger W, Beier S, Pollow K, Garfield R, Shi SO, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003;68:891–905
  12. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care. 2000;5(Suppl 3):25–33
  13. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric. 2004;7:189–196
  14. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821
  15. Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric. 2004;7:103–111
  16. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12:716–727

PII: S0378-5122(07)00122-3

doi: 10.1016/j.maturitas.2007.03.004

Maturitas
Volume 57, Issue 4 , Pages 361-369 , 20 August 2007

Article Tools

* Image Usage & Resolution